Drug
Gabapentin enacarbil clinical trials
Also written XP13512, GSK1838262 and Horizant.
- studies test it
- 31
- open now
- 1
- in phase 3
- 6
- first study started
- 2006
Keep track of what changes. Save the gabapentin enacarbil studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2008 (6)
| Year | Studies |
|---|---|
| 2006 | 4 |
| 2007 | 5 |
| 2008 | 6 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 9
- Phase 3
- 6
- Phase 4
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 6
XenoPort, Inc. (17) · Astellas Pharma Inc (7) · Arbor Pharmaceuticals, Inc. (1) · The Cleveland Clinic (1) · University of Missouri-Columbia (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · University of Texas at Austin (1) · Theresa Zesiewicz, MD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gabapentin enacarbil is read from its arms, and is right about nine times in ten.
Testing it · 31
- Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's DiseaseRecruitingPhase 4University of Texas at AustinNCT03082755Written as Gabapentin Enacarbil
- A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome PatientsCompletedPhase 4Astellas Pharma IncNCT03053427Written as Gabapentin enacarbil
- Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal ImpairmentCompletedPhase 4Astellas Pharma IncNCT01981941Written as Gabapentin enacarbil
- An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug UsersCompletedPhase 4Arbor Pharmaceuticals, Inc.NCT06097676Written as Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg
- Effect of Gabapentin Enacarbil on Opioid Consumption and Pain ScoresCompletedNot applicableThe Cleveland ClinicNCT02840240Written as Gabapentin enacarbil
- The Effect of Horizant (Gabapentin Enacarbil) on AugmentationCompletedNot applicableUniversity of Missouri-ColumbiaNCT02642315Written as Horizant
- Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg SyndromeTerminatedPhase 4Theresa Zesiewicz, MDNCT02117076Written as Gabapentin enacarbil extended release
- An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSStatus unknownPhase 4XenoPort, Inc.NCT02560766Written as HORIZANT 300 mg
- An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSStatus unknownPhase 4XenoPort, Inc.NCT02633683Written as HORIZANT 600 mg
- Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment StudyCompletedPhase 4XenoPort, Inc.NCT01668667Written as GSK1838262 600 mg
- A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLSWithdrawnPhase 1XenoPort, Inc.NCT02633657Written as HORIZANT 300 mg
- HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use DisorderCompletedPhase 2National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT02252536Written as gabapentin enacarbil
- ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and HaemodialysisCompletedPhase 1Astellas Pharma IncNCT02629224Written as ASP8825
- Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome PatientsCompletedPhase 3Astellas Pharma IncNCT02658188Written as ASP8825
- ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825CompletedPhase 1Astellas Pharma IncNCT02632331Written as ASP8825
- Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs SyndromeStatus unknownPhase 4Cleveland Sleep Research CenterNCT02424695Written as Gabapentin Enacarbil (GEn)
- ASP8825 - Study in Patients With Restless Legs SyndromeCompletedPhase 2Astellas Pharma IncNCT00530530Written as ASP8825
- Simulated Driving Study in Restless Legs SyndromeCompletedPhase 2XenoPort, Inc.NCT01332318Written as XP13512
- A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)CompletedPhase 2XenoPort, Inc.NCT00619476Written as GEn 1200mg/day
- A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)CompletedPhase 2XenoPort, Inc.NCT00643760Written as GEn 1200mg/day
Codes
What other systems call gabapentin enacarbil · ClinicalTrials.gg INT004712
- UNII (FDA) 75OCL1SPBQGABAPENTIN ENACARBILConfirmed FDA, Wikidata
- RxNorm 1101333Confirmed FDA, Wikidata
- Wikidata Q5515257gabapentin enacarbilConfirmed FDA, Wikidata
- NCI Thesaurus C79579Gabapentin EnacarbilOne source FDA
- DrugBank DB08872One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 75OCL1SPBQ | GABAPENTIN ENACARBIL | Confirmed FDA, Wikidata |
| RxNorm | 1101333 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5515257 | gabapentin enacarbil | Confirmed FDA, Wikidata |
| NCI Thesaurus | C79579 | Gabapentin Enacarbil | One source FDA |
| DrugBank | DB08872 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.